Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Baseline visit

You attend the first study visit after enrollment. during this visit, a complete medical history is recorded, blood samples are taken, vital signs are measured, and disease activity is evaluated using standard rheumatoid arthritis assessments.

Randomization

Based on the study design, you are assigned to receive either the test medication (afimkibart, also called ro7790121) or a matching placebo. the assignment is done by the study staff and you are not informed of which you receive.

Initial dosing

You receive the first dose as a subcutaneous injection (injection under the skin). the medication is supplied as a solution for injection/infusion. the exact dose and dosing schedule are defined by the trial protocol and are administered at each scheduled visit.

Regular follow‑up visits

You return to the clinic at regular intervals defined by the protocol (for example, every 4 to 8 weeks). at each visit you:

- receive the next subcutaneous injection of afimkibart or placebo,

- undergo safety assessments, including checking for any adverse events,

- have blood drawn for laboratory tests,

- have vital signs measured, and

- have disease activity re‑evaluated.

Ongoing treatment period

The injection schedule continues for the duration of the extension study, which may last several years until the study end date of 2033‑07‑09. you remain on the assigned treatment for the entire period unless a serious safety concern requires discontinuation.

Final study visit

At the end of the study, you attend a final visit. comprehensive assessments are performed, including safety evaluation, laboratory testing, vital signs, and disease‑activity measurements. the final blood sample is taken to measure the serum concentration of afimkibart.